← Back to headlines
CRISPR Therapeutics Reports $116M FY25 Revenue Driven by CASGEVY Growth
CRISPR Therapeutics announced $116 million in revenue for fiscal year 2025, primarily attributed to the growth of its gene-editing therapy, CASGEVY.
11 Mar, 20:56 — 11 Mar, 20:56
Sources
Showing 1 of 1 sources
